Related Experiment Video

Updated: May 20, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Rosiglitazone and AS601245 decrease cell adhesion and migration through modulation of specific gene expression in

Angelo Cerbone1, Cristina Toaldo, Rosalba Minelli

  • 1MerckSerono Ivrea - RBM SpA, Istituto di Ricerche Biomediche A Marxer, Colleretto Giacosa, Turin, Italy.

Plos One
|July 5, 2012
PubMed

Insights

Combining a PPARγ ligand with a JNK inhibitor significantly reduces colon cancer cell adhesion and migration. This synergistic effect involves down-regulation of β-PIX, a key protein in cell migration processes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors.
  • PPARγ activation reduces cancer cell adhesion and motility.
  • JNK-mediated phosphorylation negatively regulates PPARγ activity.

Purpose of the Study:

  • To investigate if inhibiting JNK activity enhances PPARγ ligand effectiveness.
  • To analyze the combined effects of a PPARγ ligand and a JNK inhibitor on colon cancer cell adhesion and migration.
  • To identify genes involved in these cellular processes.

Main Methods:

  • Utilized rosiglitazone (PPARγ ligand) and AS601245 (JNK inhibitor) on colon cancer cell lines (CaCo-2, HT29, SW480).
  • Assessed cell adhesion and migration.
  • Performed microarray analysis to identify gene expression changes.
  • Conducted Western blot analysis and gene transfection experiments.

Main Results:

  • Both rosiglitazone and AS601245 individually inhibited cell adhesion and migration.
  • Combined treatment showed a greater reduction in adhesion and migration.
  • Down-regulation of fibrinogen chains and release was observed.
  • Combined treatment significantly down-regulated ARHGEF7/β-PIX gene and protein.
  • β-PIX gene transfection abrogated the inhibitory effects of the treatments on cell migration.

Conclusions:

  • Combined PPARγ ligand and JNK inhibitor treatment enhances the inhibition of colon cancer cell migration.
  • β-PIX protein plays a crucial role in mediating the anti-migratory effects.
  • This highlights a synergistic interaction between PPARγ ligands and anti-inflammatory agents for cancer therapy.

More Related Videos

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator06:08

Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator

Published on: May 19, 2023

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...